Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

PURPOSE Bec2 is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is of neuroectodermal origin. We assessed whether Bec2/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation. PATIENTS AND METHODS Patients were randomly assigned to receive five vaccinations of Bec2 (2.5 mg)/BCG vaccine or follow-up. Vaccination was given over a 10-week period. The sample size was targeted to detect an increase in median survival of 40% after random assignment, and stratification was by performance status, response, and institution. Quality of life was assessed by using the European Organisation for Research and Treatment of Cancer instrument. Humoral response was assessed in patients who received vaccination. RESULTS A total of 515 patients were randomly assigned. The primary toxicities of vaccination were transient skin ulcerations and mild flu-like symptoms. There was no improvement in survival, progression-free survival, or quality of life in the vaccination arm. Median survival from randomization was 16.4 and 14.3 months in the observation and vaccination arms (P = .28), respectively. Among vaccinated patients, a trend toward prolonged survival was observed in those (one third) who developed a humoral response (P = .085). Multivariate analysis showed a positive impact on survival by prior treatment with concomitant chemoradiotherapy, prophylactic cranial irradiation, female sex, low lactate dehydrogenase, and normal platelets. CONCLUSION Vaccination with Bec2/BCG has no impact on outcome of patients with limited-disease SCLC responding to combined-modality treatment. Vaccination strategies in SCLC may still be warranted using vaccines that produce a better immunologic response.

[1]  T. Warner,et al.  Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Niculescu-Duvaz.  Technology evaluation: EMD-273063, EMD Lexigen. , 2004, Current opinion in molecular therapeutics.

[3]  M. Kris,et al.  Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin , 2004, Clinical Cancer Research.

[4]  F. Berthold,et al.  Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Chapman,et al.  A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. , 2004, Vaccine.

[6]  P. Chapman,et al.  Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside , 2004, Clinical Cancer Research.

[7]  J. Wolchok,et al.  Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Carbone,et al.  Lung cancer vaccines and gene therapy. , 2003, Lung cancer.

[9]  P. Chapman.  Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. , 2003, Current opinion in investigational drugs.

[10]  A. Turrisi.  Limited stage small cell lung cancer: Treatment and therapy , 2003, Current treatment options in oncology.

[11]  G. Giaccone,et al.  Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Scott,et al.  Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Cella,et al.  Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Shitara,et al.  Recombinant antibodies against ganglioside expressed on tumor cells , 2000, Cancer Chemotherapy and Pharmacology.

[15]  B. Bergman,et al.  Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. , 2000, Lung cancer.

[16]  M. Marangolo,et al.  Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Kris,et al.  Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. , 1999, Seminars in oncology.

[18]  M. Kris,et al.  Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[20]  M. Kris,et al.  Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  K. Cantell,et al.  Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[23]  G. Giaccone,et al.  Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. , 1997, European journal of cancer.

[24]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[25]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides , 1997, International journal of cancer.

[26]  R. Allman,et al.  Ganglioside expression in lung cancer cell lines. , 1997, Lung cancer.

[27]  K. Cantell,et al.  Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[28]  M. Paesmans,et al.  Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Houghton,et al.  Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Larson,et al.  Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial , 1996, European Journal of Nuclear Medicine.

[31]  J. Crowley,et al.  Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Old,et al.  Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma , 1995, International journal of cancer.

[33]  J. Jett,et al.  Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. deBoisblanc,et al.  Facilitation of fiberoptic nasotracheal intubation in a morbidly obese patient by simultaneous use of nasal CPAP. , 1994, Chest.

[35]  J. Jett,et al.  Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. , 1993, Journal of the National Cancer Institute.

[36]  G. Giaccone,et al.  Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J P Pignon,et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.

[38]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Månsson,et al.  Gangliosides and neutral glycosphingolipids of normal tissue and oat cell carcinoma of human lung. , 1986, Biochimica et biophysica acta.

[40]  M. Zelen.  Keynote address on biostatistics and data retrieval. , 1973, Cancer chemotherapy reports. Part 3.

[41]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[42]  E. A. Velde,et al.  Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report , 2004, Cancer Immunology, Immunotherapy.

[43]  A. Houghton,et al.  Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  K. Cantell,et al.  Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.

[45]  P. Rondoni.  [Report of the activities of the Istituto nazionale per lo studio e la cura dei tumori, di Milano, 1952]. , 1953, Tumori.